[Anidulafungin: a new therapeutic option in systemic candidiasis].
The increasing incidence of invasive fungal infections, epidemiological changes in these infections, and safety or interactions issues that might limit the use of traditional antifungal therapies explain the need for new antifungal agents. Anidulafungin is a new echinocandin with excellent activity on most Candida as well as on Aspergillus species. Its pharmacokinetic properties allow its administration without dosage adjustments in patients with hepatic and renal impairment and account for the absence of drug interactions. Anidulafungin has showed its efficacy and good tolerability in systemic candidiasis of non-neutropenic adults, including candidemia especially in fragile patients.
Lanternier
F
F
Service des maladies infectieuses et tropicales, centre d'infectiologie Necker-Pasteur, groupe hospitalier Necker-Enfants-Malades, faculté de médecine Paris Descartes, 149, rue de Sèvres, 75743 Paris cedex 15, France.
Lortholary
O
O
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D054714:Echinocandins / Q000627:therapeutic use*; D006801:Humans
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin